Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment

Oct 11, 2013International clinical psychopharmacology

Effects of Adding Extended-Release Quetiapine in Depression Patients Already Taking SSRI or SNRI Medications

AI simplified

Long Covid on OpenScience ↗PubMed ↗DOI ↗

Abstract

Adjunct quetiapine XR (150 and 300 mg/day) significantly reduced depression scores in patients with major depressive disorder (MDD) at week 6.

Quetiapine XR 150 mg/day and 300 mg/day, when added to SSRIs, led to a reduction in the Montgomery Åsberg Depression Rating Scale (MADRS) total score compared to placebo+SSRI.
The least squares mean change in MADRS score was -14.70 for 150 mg/day and -14.72 for 300 mg/day, both statistically significant with P<0.05.
Similarly, quetiapine XR at 150 mg/day and 300 mg/day combined with SNRIs also showed a significant reduction in MADRS score versus placebo+SNRI.
The least squares mean change for quetiapine XR 150 mg/day was -14.68 and for 300 mg/day was -14.99, with P<0.01 for both.
This analysis included data from two 6-week, double-blind, randomized, placebo-controlled trials.

AI simplified

This pooled analysis evaluated the efficacy of extended-release quetiapine fumarate (quetiapine XR) adjunct to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) in patients with major depressive disorder (MDD). Pooled data were analyzed from two 6-week, double-blind, randomized, placebo-controlled trials of adjunct quetiapine XR (150 and 300 mg/day) in patients with MDD and inadequate response to initial antidepressant monotherapy. This post-hoc analysis included evaluation of change from randomization at week 6 in Montgomery Åsberg Depression Rating Scale (MADRS) total scores (primary endpoint), and week 6 MADRS response and remission rates for quetiapine XR as an adjunct to ongoing SSRI or SNRI. In total, 189, 178, and 202 patients received quetiapine XR 150 mg/day+SSRI, 300 mg/day+SSRI, and placebo+SSRI, respectively, whereas 82, 90, and 76 patients, respectively, received quetiapine XR 150 mg/day+SNRI, 300 mg/day+SNRI, and placebo+SNRI. At week 6, quetiapine XR 150 mg/day+SSRI and 300 mg/day+SSRI reduced the MADRS total score from randomization versus placebo+SSRI [least squares mean (LSM) change, -14.70 (P<0.05) -14.72 (P<0.05) vs. -12.59, respectively]. Quetiapine XR 150 mg/day+SNRI (LSM change, -14.68, P<0.01) and 300 mg/day+SNRI (LSM change, -14.99, P<0.01) also reduced the MADRS total score from randomization at week 6 versus placebo+SNRI (-10.77). In conclusion, in patients with MDD and inadequate response to ongoing antidepressant, adjunct quetiapine XR (150 and 300 mg/day) was effective in both SSRI and SNRI subgroups.

Full Text

Full text is available at the source.

View full text ↗

Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the long covid brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the long covid brief